@entity1311 , XXXX , and @entity1814 as second-line treatment for @entity1 with metastatic urothelial carcinoma: a phase II study of the SUOC group.

@entity1 @entity632 @entity137 @entity11721 @entity417 @entity882 @entity5 @entity900 @entity1311 @entity448 @entity1398 @entity492 @entity5713 @entity493 @entity1260 @entity1499 @entity136 @entity1814
There is no standard second-line chemotherapy treatment for recurrent or metastatic @entity5 (MUC). The purpose of this phase II study was to evaluate the efficacy and @entity137 of the three-drug combination of @entity1311 , @entity1260 , and @entity1814 (TIN). @entity1 with MUC were eligible after treatment failure with @entity1499 , @entity5713 , @entity632 , and @entity900 , or @entity136 and @entity900 . Doses for TIN therapy were @entity1311 175   mg/m2 on day 1, @entity1260 1500   mg/m2 on days 1-3, and @entity1814 70   mg/m2 on day 1, every 4   weeks. @entity5 response, the primary efficacy parameter, was assessed according to unidimensional measurements (Response Evaluation Criteria in @entity5 criteria, version 1.0). Secondary efficacy parameters were overall survival (OS) and progression-free survival (PFS). @entity137 was assessed according to the National @entity5 Institute Common @entity137 Criteria, version 3.0. A total of 45 @entity1 (13 females and 32 males) with MUC were evaluable for response and @entity137 . The overall response rate was 40.0%. Median PFS time was 4.0   months (95% confidence interval [CI], 4.6-11.6). Median OS time was 8.9   months (95% CI, 10.5-18.9). Grade 3 or 4 hematologic adverse events were @entity1398 (95.6%), @entity417 (15.6%), and @entity882 (17.8%). The most common grade 3 or 4 non-hematologic adverse events were @entity448 (4.4%) and elevated @entity492 transaminase/ @entity493 transaminase (2.2%). No toxic death was observed. The main limitation of this study is that only 10 @entity1 (22.2%) who were previously treated with @entity136 and @entity900 were included. In conclusion, @entity11721 as second-line treatment for MUC is an active regimen with a manageable @entity137 profile.
